Reply: 1

Reply: 1

To the Editor: We would agree with Dr Melamed1 that our concerns about patients receiving venom immunotherapy (VIT) who are taking angiotensin-converting enzyme inhibitors (ACEIs) being at increased risk for anaphylaxis from their immunotherapy2 might also be appropriate for other types of immunothe...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of allergy and clinical immunology 2004-06, Vol.113 (6), p.1225
Hauptverfasser: Ober, Andrew I, MacLean, James A, Hannaway, Paul J
Format: Artikel
Sprache:eng
Schlagworte:
Drug therapy
Medical research
Patients
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:To the Editor: We would agree with Dr Melamed1 that our concerns about patients receiving venom immunotherapy (VIT) who are taking angiotensin-converting enzyme inhibitors (ACEIs) being at increased risk for anaphylaxis from their immunotherapy2 might also be appropriate for other types of immunotherapy as well.
ISSN:0091-6749
1097-6825
DOI:10.1016/j.jaci.2004.01.775